Sensors for fluorescence and magnetic resonance imaging
The present invention generally relates to agents and compositions having MRI and/or optical signals, and methods for their use in the determination of an analyte. In some cases, an optical, MRI, or other signal produced by the agent or composition may be affected by the presence of an analyte. Some embodiments of the present invention may provide agents or compositions which are cell permeable. Examples of analytes that may be determined by the present invention include zinc ions, calcium ions, and other biological analytes.
1. A method for determining an analyte, comprising:
providing a MRI or optical agent having the formula,
wherein:
A is a group comprising an aryl group, optionally substituted;
B is a chelator group comprising at least one aromatic heterocycle;
X 1 and X 2 can be the same or different and each is a heteroatom;
L 1 and L 2 can be the same or different and each is a group comprising an alkyl or heteroalkyl group, optionally substituted; and
Q 1 and Q 2 can be the same or different and each is a group comprising a binding moiety for an analyte;
exposing the agent to a sample suspected of containing an analyte, wherein the agent interacts with the analyte, if present, to generate an analyte-bound MRI signal or optical signal that is shifted relative to the MRI signal or optical signal absent the analyte; and
determining the shift in the MRI signal or an optical signal of the agent, or lack thereof, thereby determining the presence and/or amount of the analyte in the sample.
2. A method as in claim 1 , further comprising the act of:
inserting the MRI or optical agent into a cell or portion of a cell and the analyte, if present, is within the cell.
3. A method as in claim 1 , wherein the analyte is present within a subject.
4. A method as in claim 1 , wherein the analyte is present within a cell.
5. A method as in claim 1 , wherein the analyte is a metal ion or nitric oxide.
6. A method as in claim 1 , wherein the analyte is Zn 2+ , Ca 2+ , Hg 2+ , Cd 2+ , or Pb 2+ .
7. A method as in claim 1 , wherein the shift in the magnetic resonance imaging signal comprises a shift in T1 relaxivity.
8. A method as in claim 1 , wherein the shift in the magnetic resonance imaging signal comprises a shift in T2 relaxivity.
9. A method as in claim 1 , wherein the shift in the optical signal comprises an increase or decrease in luminescence intensity, or a shift in luminescence wavelength.
10. A method as in claim 1 , wherein the interaction between the agent and the analyte comprises a binding event between the binding moiety and the analyte.
11. A method as in claim 1 , wherein the chelator group comprises at least one aromatic heterocycle and comprises a metal ion bound to the at least one aromatic heterocycle.
12. A method as in claim 1 , wherein the agent is not linked to a carrier molecule.
13. A method as in claim 1 , wherein the chelator group comprises a polycyclic group.
14. A method as in claim 1 , wherein the chelator group is a porphyrin, expanded porphyrin, or polypyrrole group, optionally substituted.
15. A method as in claim 1 , wherein the binding moiety is dipicolylamine (DPA) or 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA).
16. A method as in claim 11 , wherein the chelator group comprises a metal ion bound to the at least one aromatic heterocycle.
17. A method as in claim 16 , wherein the metal ion is a paramagnetic metal ion.
18. A method as in claim 1 , wherein the agent has the formula,
wherein:
A is a group comprising an aryl or heteroaryl group, optionally substituted;
X 1 and X 2 can be the same or different and each is a heteroatom;
L 1 and L 2 can be the same or different and each is a group comprising an alkyl or heteroalkyl group, optionally substituted; and
Q 1 and Q 2 can be the same or different and each is a group comprising a binding moiety for an analyte;
R 1-3 can be the same or different and are groups which are together selected such that the compound is water-soluble;
R 4-7 can be the same or different and each is a group comprising halide, hydroxyl, alkyl, or aryl, and each is optionally substituted;
M is absent or a metal ion such that, when M is absent, the compound comprises a free base porphyrin group and, when M is present, the compound comprises a metalloporphyrin group.
19. A method as in claim 18 , wherein:
A is phenyl or pyridine;
both X 1 and X 2 are N, O, or S;
both Q 1 and Q 2 are dipicolylamine (DPA) or 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA);
R 1-3 are each sulfonated benzene or N-alkylated pyridinium; and
M is absent or Mn 3+ , Mn 2+ , Fe 3+ , Fe 2+ , Zn 2+ , Mg 2+ or Al 3+ .
20. A method as in claim 1 , wherein the agent has the structure,
wherein L is an ethylene group and M is Mn 3+ , Mn 2+ , Fe 3+ , or Fe 2+ .
21. A method as in claim 1 , wherein the agent has the structure,
wherein M is Zn 2+ , Mg 2+ , Al 3+ , Mn 3+ , Mn 2+ , Fe 3+ , or Fe 2+ ; R 8 is CH 2 CO 2 H or CH 2 CO 2 R 9 ; and R 9 is alkyl.
22. A method as in claim 1 , wherein the agent has the structure,
wherein M is Zn 2+ , Mg 2+ , Al 3+ , Mn 3+ , Mn 2+ , Fe 3+ , or Fe 2+ ; R 10 is CH 2 CO 2 H or CH 2 CO 2 R 12 ; R 11 is hydrogen or alkyl; and R 12 is alkyl.